2020
Associations of Long Chain Polyunsaturated Fatty Acid Biomarkers with Affective Symptoms and Cognition in Women Beginning Chemotherapy for Breast Cancer
Zhang Z, Ormiston K, Orchard T, Lustberg M, Schnell P. Associations of Long Chain Polyunsaturated Fatty Acid Biomarkers with Affective Symptoms and Cognition in Women Beginning Chemotherapy for Breast Cancer. Current Developments In Nutrition 2020, 4: nzaa044_065. PMCID: PMC7257812, DOI: 10.1093/cdn/nzaa044_065.Peer-Reviewed Original ResearchSerum fatty acidsNon-significant trendBreast cancerState-Trait Anxiety InventoryAffective symptomsDouble-blinded randomized studyLong-chain omega-3 fatty acidsOmega-3 fatty acidsBaseline fatty acidsSerum FA profilesBreast cancer patientsFatty acidsResults Preliminary resultsRandomized studySerum levelsCancer patients
2010
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
Lustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCamptothecinCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansIrinotecanLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMitomycinNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeConceptsMitomycin CDay 1Day 2Phase II Randomized StudyComplete pathologic responsePhase II evaluationGastroesophageal junction adenocarcinomaUnresectable esophagealEvaluable patientsGastroesophageal adenocarcinomaJunction adenocarcinomaPathologic responseRandomized studyArm AGastroesophageal junctionFuture trialsEsophageal cancerII evaluationSevere toxicityPatientsIrinotecanResponse ratePhase IAdenocarcinomaTopoisomerase 1